Vaxcyte Inc (PCVX): GSK to acquire clinical-stage biopharmac...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	0
Posts	18
Boards Moderated	0
Alias Born	07/02/2015

Wheat123

Re: None

Tuesday, 05/31/2022 8:40:50 AM

Tuesday, May 31, 2022 8:40:50 AM

GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.

https://affinivax.com/gsk-to-acquire-clinical-stage-biopharmaceutical-company-affinivax-inc/

GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones

Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPS technology

Supports development of a strong portfolio of innovative vaccines and specialty medicines

"Affinivax has developed the Multiple Antigen Presenting System (MAPS), a novel technology that supports higher valency than conventional conjugation technologies, enabling broader coverage against prevalent pneumococcal serotypes and potentially creating higher immunogenicity than current vaccines. Affinivax’s most advanced vaccine candidate (AFX3772) includes 24 pneumococcal polysaccharides plus two conserved pneumococcal proteins (compared to up to 20 serotypes in currently approved vaccines). A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development."

Seems familiar...